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Objective:  For  extended-release  drugs  with  multi-compartment  kinetics,  such  as  topiramate,  effective
half-life  (t1/2eff) may  be a more  clinically  relevant  parameter  than  elimination  half-life  (t1/2z). Using  top-
iramate  as a real-life  example,  the objective  was to compare  these  half-life  values  for immediate-  and
extended-release  topiramate  (TPM-IR  and  USL255,  respectively)  to  understand  how  drug  pharmacoki-
netics  may  impact  drug  dosing  recommendations.
Methods:  The  t1/2z and  t1/2eff for USL255  and  TPM-IR  were  compared  using  data  from  a phase  I study  (N  =  36)
of  200  mg  USL255  administered  once  daily  (QD)  or TPM-IR  twice  daily  (BID);  effect  of  sampling  duration
on  t1/2z was  investigated.  To  further  explore  the relationship  between  half-life  and  dosing,  steady-state
PK  was  simulated  for USL255  and TPM-IR.
Results:  As previously  reported,  mean  t1/2z was  similar  between  USL255  (80.2 h)  and  TPM-IR  (82.8  h);  TPM-
IR t1/2z was  ∼4 times  longer  than  reported  in the Topamax  label  (21  h).  In contrast,  USL255  displayed  a
1.5  fold  longer  t1/2eff (55.7  vs  37.1  h  for TPM-IR).  When  t1/2z was  calculated  from  48 to  336 h, values
ranged from  28.8 to  82.8 h. Simulated  steady-state  PK proﬁles  of  USL255  QD  exhibited  reduced  plasma
ﬂuctuations  during  a dosing  interval  vs  TPM-IR  QD  or BID.
Signiﬁcance:  As  expected  for the  same  moiety,  t1/2z of  USL255  and  TPM-IR  were  similar;  however,  the
longer  t1/2eff for USL255  better  approximates  differences  in recommend  dosing  (QD  USL255  vs  BID  TPM-
IR). Further,  sampling  duration  impacted  t1/2z, diminishing  its predictive  value  for determining  dose
regimens;  sampling-time  differences  may  also  explain  t1/2z discrepancy  between  TPM-IR  here  versus
Topamax  label.  As  expected,  steady-state  simulations  conﬁrm  that  although  TPM-IR  has  a long  t1/2z,
taking  TPM-IR  QD  would  lead to large plasma  ﬂuctuations.  These  data  demonstrate  that  t1/2z may  be
less  clinically  meaningful  than  t1/2eff, and using  t1/2z for some  drugs  may  lead  to erroneous  conclusions
regarding  dosing  regimens.
©  2016  The  Author(s).  Published  by Elsevier  B.V.  This  is  an  open  access  article  under  the  CC. Introduction
Appropriate interpretation of pharmacokinetic (PK) data is cru-
ial when optimizing antiepileptic drug (AED) therapy. It is equally
mportant that one not misapply either pharmacokinetic data, or
he underlying mathematical principles of PK when constructing
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an individualized AED dosing regimen. One of the oldest, and most
fundamental concepts in pharmacotherapy is that of drug half-life
(t1/2). The simple deﬁnition of t1/2 is the time interval over which
the amount of drug in the body is decreased by one-half. A common
misconception is that t1/2 is synonymous with clearance, which is
not completely accurate. In fact, t1/2 is a hybrid parameter that takes
into account drug clearance as well as its volume of distribution (ie,
drug distribution between plasma and the rest of the body after dos-
ing). Therefore, a better way of viewing t1/2 is that it is a predictor
of drug accumulation and ﬂuctuation in plasma concentration.
Clinicians may use t1/2 to guide them in individualizing dosage
regimens for patients. Understanding t1/2 is particularly important
when determining dosing intervals for chronically-administered
e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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rugs, as dosing adjustments may  impact a drug’s systemic expo-
ure (ie, area under the concentration-time curve [AUC]) and
lasma ﬂuctuations. For example, if a drug is administered at a
teady-state frequency equal to its t1/2, then AUC during that dos-
ng interval will be twice that seen following a single dose (Sahin
nd Benet, 2008); this is due to drug accumulation over time as a
epeated dose is given prior to disappearance of the previous dose.
iving a drug more frequently than its t1/2 will result in more drug
ccumulation, with the opposite occurring if that drug is given less
requently than the t1/2 (Grover and Benet, 2011). With regards to
lasma ﬂuctuations, dosing a drug more frequently than its t1/2 will
esult in a ﬂatter plasma concentration-time curve (ie, less ﬂuctua-
ion) than if that same daily dose were being given less frequently
Grover and Benet, 2011).
Though half-life is a key pharmacokinetic parameter in deter-
ining drug dosing, it is important to note that drugs may  exhibit
ultiple half-lives, depending on how they distribute into tissues
hroughout the body following dosing. As such, different methods
an be used to calculate a drug’s half-life. In practice, clinicians will
ften use terminal elimination half-life (t1/2z) to guide drug dosing,
s this is the most widely published half-life value and the one
ypically reported in prescribing information. The t1/2z for a drug
s deﬁned as drug elimination during the terminal phase, which is
he ﬁnal elimination phase following drug absorption and redistri-
ution into body tissues.
For drugs with simple linear pharmacokinetics, t1/2z may  be
n accurate measure of a drug’s half-life. However, for drugs with
lower absorption, multi-compartment distribution into different
issues, and multi-exponential disposition, t1/2z may  be a poor pre-
ictor of drug accumulation and ﬂuctuation. This is illustrated in
ig. 1A, which depicts a hypothetical plasma concentration-time
roﬁle for a drug that distributes into multiple compartments. As
1/2z describes drug elimination during the terminal phase (after
rug absorption and distribution has entirely completed), t1/2z may
nly describe a very small fraction of the plasma concentration-
ime curve (Bialer and Soares-da-Silva, 2012). Therefore, t1/2z will
robably not describe concentration decline during a dosage inter-
al for drugs with more complex absorption and distribution
haracteristics, such as extended-release formulations that are
peciﬁcally designed to have a slower absorption proﬁle. Another
imitation of t1/2z is that the value can be impacted by PK assay
ethods, including sampling duration, assay sensitivity, and sam-
ling frequency. For example, sampling duration (ie, the duration of
ime over which plasma samples are taken) can change the phase
hen half-life is measured, thereby impacting the resulting t1/2z
alue (Fig. 1A).
Given that most antiepileptic drugs (AEDs) will likely display
ulti-compartment kinetics, which half-life should the clinician
se? If our clinical objective is to dose a drug that can be given as
nfrequently as possible, with minimal plasma concentration ﬂuc-
uation and consistent exposure during the dosage interval, then
se of the commonly accepted and published value of t1/2z may
e incorrect for many AEDs. Indeed, using this value may  result in
uboptimal dosing predictions (Sahin and Benet, 2008). Therefore,
 more clinically relevant half-life measure may be effective half-
ife (t1/2eff), which describes the rate of drug loss across the entire
osing interval.
Unlike t1/2z, which is calculated using the slope of the last drug
limination phase following single-dose administration (Fig. 1A;
q. (1)), t1/2eff takes into consideration the entire concentration-
ime proﬁle of a drug. The t1/2eff is calculated based on both the
rug-dosing interval and drug accumulation over time following
ultiple-dose administration (Fig. 1B; Eq. (2)) (Boxenbaum and
attle, 1995). As a result, t1/2eff is expected to be less affected by
ampling duration compared with t1/2z, and its calculation only
equires sampling over the dosing interval following a single dosearch 129 (2017) 26–32 27
and at steady state. Thus, using t1/2eff to guide dosing may  be partic-
ularly beneﬁcial when long-term maintenance of therapeutic levels
is required.
Overall, the use of t1/2eff in lieu of t1/2z may be particularly
beneﬁcial for extended-release AEDs with multi-compartment
kinetics. Topiramate (TPM) is one such agent; Gidal and Lensmeyer
demonstrated that TPM partitions in a saturable manner into ery-
throcytes (Gidal and Lensmeyer, 1999). The release of TPM from this
high-afﬁnity red blood cell compartment—presumably to carbonic
anhydrase—likely contributes to reduced apparent oral clearance
and volume of distribution at low concentrations (Shank et al.,
2005). These properties of TPM make it an ideal candidate to com-
pare the clinical utility of these two  half-life measures.
Using TPM as a real-life example, the objective of this
manuscript is to understand how the pharmacokinetics of
immediate-release (IR) and extended-release (XR) formulations
may  impact drug dosing recommendations. First, the t1/2eff and
t1/2z of IR and XR TPM will be compared to demonstrate how both
formulation differences and methodology impact half-life values.
Additionally, steady-state proﬁles will be simulated to understand
how varying drug dosing (ie, once- vs twice-daily dosing) impacts
the pharmacokinetics of IR versus XR formulations. Together, the
use of TPM—an AED with IR and XR formulations—will demonstrate
which half-life measure may be more clinically-useful in determin-
ing appropriate dosing intervals.
2. Methods
2.1. Comparison of elimination and effective half-Lives for
USL255 and TPM-IR
The two TPM formulations evaluated were once-daily (QD)
USL255, Qudexy® XR (topiramate) extended-release capsules
(Upsher-Smith Laboratories, Inc. (Qudexy®, 2015)) and twice-daily
(BID) IR topiramate (TPM-IR; Topamax®; Janssen Pharmaceuticals
(Topamax®, 2009)). Half-life values were assessed from a phase
I, randomized (N = 36), open-label, crossover study of single-dose
USL255 200 mg and 2 doses of TPM-IR 100 mg  dosed every 12 h
(Lambrecht et al., 2011). The t1/2z and t1/2eff for USL255 and TPM-
IR were previously calculated (Eqs. (1) and (2)) (Lambrecht et al.,
2011). In brief, t1/2z is calculated by dividing the natural log of 2 by
the slope of the last phase (z), which is dependent on the blood
sampling duration used for PK analyses (Fig. 1, Eq. (1)).
t1/2z = ln2/z (1)
In contrast, t1/2eff is calculated based on dosing interval
() and drug accumulation over time following multiple-dose
administration (ie, drug accumulation index [Rac = steady-state
AUC0-/single-dose AUC0-]; Eq. (2)).
t1/2eff =  ∗ ln2/ln[Rac/(Rac − 1)] (2)
To determine how the plasma sampling duration for PK calcula-
tions can impact half-life, t1/2z was  calculated using data from the
48, 72, 168, 264, and 336 h PK sampling times of the phase I study
for both USL255 and TPM-IR. Detailed information regarding par-
ticipants and topiramate analyses are described in Lambrecht et al.
(Lambrecht et al., 2011).
2.2. Simulated steady-state pharmacokinetic proﬁles for USL255
and TPM-IRSimulations were used to predict steady-state plasma
concentration-time proﬁles of USL255 administered QD and
TPM-IR 200 mg  administered QD or BID; approved dosing is QD
for USL255 and BID for TPM-IR (Qudexy®, 2015; Topamax®, 2009).
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Fig. 1. Hypothetical Proﬁles Used to Calculate Elimination and Effective Half-Lives.
(A)  Illustrated here is a hypothetical plasma concentration-time proﬁle following a single dose of a 3-compartment drug. In the  phase, a rapid decrease in plasma levels is
due  to drug distribution from circulation (central compartment) into body tissues (peripheral compartments); this phase ends with pseudo-equilibrium of drug concentration
between the central and peripheral compartments. The  phase describes a slower decrease in plasma drug levels due to drug metabolism and excretion from the body. The
  phase can occur later when tissue-bound drug is released into circulation then eliminated from the body; the  phase may be associated with very small and insigniﬁcant
amount of drug distribution. The slope of the last phase (z) is used to calculate t1/2z. In this example, the  phase would be used, as the sampling duration extended to 24 h.
If  the sampling duration was  only 12 h, the  phase would be used to calculate t1/2z. Together, this ﬁgure illustrates how sampling duration may impact elimination half-life,
and  result in t1/2z estimates not being predictive of drug accumulation.
(B) Depicted is a hypothetical drug plasma accumulation following multiple doses of a drug dosed every 12 h. This graph describes the variables used to calculate t1/2eff: drug
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haded  boxes. In this hypothetical example,  = 12 h and Rac = 2. Figure modiﬁed from
995;  35:763–766 (Boxenbaum and Battle, 1995).
or USL255, a 2-compartment population PK model with sigmoid
bsorption and ﬁrst-order elimination was developed from data
btained from 158 healthy male and female participants enrolled
n four phase I studies (Bialer et al., 2013; Clark et al., 2014, 2016;
ambrecht et al., 2011). Covariate effects included allometric
ffects of weight on apparent oral clearance of topiramate (CL/F)
nd on apparent volume of distribution within the central com-
artment, and the effects of creatinine clearance on CL/F. TPM-IR
as simulated using a modiﬁed 2-compartment linear population
K model with ﬁrst order absorption as previously described
Girgis et al., 2010; Marathe, 2010). Covariate effects of weight on
L/F in the TPM-IR model were included.
Using the models described above, steady-state concentration-
ime proﬁles of USL255 QD and TPM-IR 200 mg/day QD or BIDC0-). AUC (area under the plasma concentration-time curve), is represented by the
enbaum H and Battle M.  Effective half-life in clinical pharmacology. J Clin Pharmacol
were simulated in a virtual population of 250 healthy individ-
uals using NOMMEM® (ICON, Ellicott City, MD), and validated
against observed data (Bialer et al., 2013). The virtual participant
population for each formulation was  generated through random
re-sampling of participant characteristics in the USL255 model
development dataset, keeping weight and creatinine clearance val-
ues together in the same individual. Steady-state simulations were
used to compare the minimum observed drug plasma concentra-
tion (Cmin), maximum observed drug plasma concentration (Cmax),
and ﬂuctuation index ([Cmax − Cmin]/Cavg*100, where Cavg is the
average drug plasma concentration) of USL255 and TPM-IR.
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Table 1
Predicted steady-state PK parameters of USL255 and TPM-IR administered once or
twice daily.
USL255 TPM-IR
QD BID QD
Cmin, g/mL
Mean (SD) 6.05 (1.53) 5.63 (1.74) 4.73 (1.99)
Median 5.96 5.62 4.51
Range 3.28–11.8 1.65–11.2 1.07–12.9
Cmax, g/mL
Mean (SD) 7.60 (1.72) 7.48 (2.39) 9.04 (3.59)
Median 7.44 7.04 8.39
Range 4.20–13.8 2.14–16.8 1.68–25.7
Fluctuation Index
Mean (SD) 0.23 (0.09) 0.28 (0.21) 0.66 (0.46)
Median 0.21 0.21 0.52
Range 0.06–0.67 0.07–1.27 0.08–2.42
Abbreviations: BID, twice daily; Cmax, maximum plasma concentration; Cmin, mini-B.E. Gidal et al. / Epileps
. Results
.1. Comparison of terminal and effective half-lives for USL255
nd TPM-IR
The half-lives of USL255 and TPM-IR were evaluated in a prior
hase I study of 36 healthy volunteers following a single dose
f 200 mg  USL255 QD and 200 mg  TPM-IR BID (Lambrecht et al.,
011). As expected, the mean t1/2z was similar for USL255 and TPM-
R (80.2 h vs 82.8 h (Lambrecht et al., 2011)), despite differences
n drug formulations and dosing recommendations. In contrast,
he t1/2eff for USL255 was 1.5 fold longer than TPM-IR (55.7 h vs
7.1 h (Lambrecht et al., 2011)). This marked difference in t1/2eff
etween an immediate- and extended-release formulation is not
nexpected, as effective half-life takes into account drug accumu-
ation over the dose interval. Further, t1/2eff values were shorter
han t1/2z for both USL255 and TPM-IR (55.7 vs 80.2 h for USL255
nd 37.1 vs 82.8 h for TPM-IR, respectively).
.2. Effect of sampling duration on terminal half-life values
For TPM-IR, mean terminal half-life of 82.8 h (Lambrecht et al.,
011), is almost 4-times longer than the 21 h value reported in the
PM-IR prescribing information (Topamax®, 2009). Because termi-
al half-life is dependent upon assay methodology, we  investigated
ampling duration as a factor for this large difference. Thus, t1/2z
as calculated for USL255 and TPM-IR using different sampling
urations from the dataset (Fig. 2). As sampling duration increased
rom 48 to 336 h, t1/2z increased for both USL255 and TPM-IR, inde-
endent of the formulation, with large ranges in value (USL255,
5.6–80.2 h; TPM-IR, 28.8–82.8 h). Interestingly, the 28.8 h half-life
bserved for TPM-IR at 48 h (Fig. 2) is in alignment with the 21 h
alf-life reported in the prescribing information, which was based
pon a 32 h sampling time (Topamax®, 2009).
.3. Simulated steady-state pharmacokinetic proﬁles for USL255
nd TPM-IR
The simulated steady-state plasma concentration-time proﬁles
or a typical individual receiving 200 mg/day USL255 or TPM-IR
dministered as a single 200 mg  dose (QD) or two 100 mg  doses
BID) are shown in Fig. 3. Validity of this simulation was supported
y the similarity between observed steady-state phase I data of
00 mg/day USL255 QD and TPM-IR BID administered for 14 days
Bialer et al., 2013) and the simulated steady-state proﬁles. Based
pon these simulations it is evident that although TPM-IR has a
ong t1/2z (>80 h), QD dosing based upon t1/2z would lead to large
lasma ﬂuctuations.
Evaluation of the recommended dosing regimen for USL255
nd TPM-IR showed that mean predicted ﬂuctuation index for
SL255 QD was 18% lower than TPM-IR BID (0.23 vs 0.28), with
 47% decrease in the maximum ﬂuctuation index (0.67 USL255
D vs 1.27 TPM-IR BID). This difference is not unexpected, due
o the greater predicted variability in Cmin and Cmax concentra-
ions with TPM-IR BID compared with USL255 QD (Fig. 3; Table 1).
igher minimum plasma concentration for USL255 may  have been
 primary reason for this difference in ﬂuctuation index, as mean
redicted Cmin for USL255 QD was 7.4% higher compared with TPM-
R BID, with little difference in mean predicted Cmax (1.5% higher
or USL255 vs TPM-IR; Table 1).
Though the comparison above included two drugs with different
ormulations (XR vs IR) and different dosing schedules (BID vs QD),
imilar trends are expected when keeping either formulation or
osing schedule consistent. For example, dosing XR and IR formu-
ations on a similar schedule would be predicted to result in large
uctuation index differences; as expected, USL255 QD had a 65%mum  plasma concentration; max, maximum; min, minimum; PK, pharmacokinetic;
QD, once daily; SD, standard deviation; TPM-IR, immediate-release topiramate;
USL255, extended-release topiramate.
lower mean predicted ﬂuctuation index versus TPM-IR QD (0.23 vs
0.66; Fig. 3; Table 1). Similarly, dosing the same formulation more
frequently would be predicted to reduce plasma ﬂuctuations; as
expected, BID administration of TPM-IR resulted in a 47% decrease
in the mean predicted ﬂuctuation index compared with QD dosing
(0.28 vs 0.66; Fig. 3; Table 1). The reduced plasma ﬂuctuation with
BID dosing was due to a 19% higher mean predicted Cmin and 17%
lower mean predicted Cmax versus QD dosing.
4. Discussion
Selection of an appropriate dosing interval is an important clin-
ical decision. While many clinicians and clinical scientists have
been taught that elimination half-life (t1/2z) is the most useful
parameter to guide dosing decisions (Sahin and Benet, 2008),
this half-life value may  not optimally characterize the steady-
state concentration-time proﬁle for many drugs (Dutta and Reed,
2006). A more appropriate parameter to predict drug accumulation
and describe elimination at steady state may  be effective half-life
(t1/2eff), which considers the entire plasma concentration-time pro-
ﬁle of the drug and may  better reﬂect total clearance (Boxenbaum
and Battle, 1995). This may  be particularly the case in situations
where clinicians opt to use newer extended-release formulations
of existing agents.
A goal of this manuscript was to use TPM as a real-life example
to understand how drug PK—including half-life—may impact drug
dosing recommendations. Results from these analyses suggest that
half-life measures can be inﬂuenced by drug formulation (ie, XR and
IR) and methodology (ie, PK sampling time). This was conﬁrmed
with observed data from TPM demonstrating that t1/2z is insensitive
to formulation differences and varies depending on drug sampling
time whereas t1/2eff may better approximate differences between
XR and IR TPM.
When determining the impact of drug formulation on PK, one
might think that an extended- and immediate-release formulation
of the same active moiety would have different half-life values.
However, the t1/2z for USL255 and TPM-IR are nearly identical
(80.2 vs 82.8 h, respectively), and no large difference in t1/2z was
observed between these 2 formulations when sampling time was
kept consistent (Fig. 2). This similar t1/2z for USL255 and TPM-IR
may  lead to the incorrect assumption that changes in plasma con-
centration over 24 h are similar between XR and IR formulations
or that IR drugs may  be dosed less frequently. In contrast, the 1.5-
fold higher t1/2eff for USL255 versus TPM-IR (55.7 vs 37.1 h) better
30 B.E. Gidal et al. / Epilepsy Research 129 (2017) 26–32
Fig. 2. Impact of Pharmacokinetic Sampling Duration on Elimination Half-Life of 200 mg USL255 and TPM-IR.
t1/2z calculated at each sampling duration (black arrows) for 200 mg/day USL255 and TPM-IR is presented under the concentration-time proﬁle for both topiramate formu-
lations.  Linear scale is shown in panel A and log scale shown on panel B. Samples for TPM-IR were taken following the 2nd BID dose (eg, 48 h equals 36 h post 2nd dose,
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bbreviations: BID, twice daily; QD, once daily; t1/2z; elimination half-life; TPM-IR, 
pproximates the difference in recommend dosing between the
 formulations (QD vs BID, respectively). Similar results for other
EDs also have demonstrated that t1/2eff may  be more clinically
eaningful than t1/2z. Dutta and Reed demonstrated that although
alproic acid has a t1/2z of 12–16 h, the t1/2eff of divalproex-ER over a
osage interval was in fact 40 h (due to its prolonged drug release),
upporting its once-per-day administration (Dutta and Reed, 2006).
ikewise, for the AED eslicarbazepine acetate, t1/2eff corresponds
ell with its once-daily dose interval. Based upon its absorption
ate as well as metabolite formation rate and dosage interval,
slicarbazepine accumulation ratio translated into an t1/2eff for esli-
arbazepine of 20–24 h, or about twice as long as its t1/2z (Bialer and
oares-da-Silva, 2012).
In addition to being unaffected by drug formulation differences,
1/2z can also be impacted by clinical methodology. As described
bove, the 82.8-h t1/2z reported for TPM-IR (Lambrecht et al., 2011)
s almost 4-times longer than the 21-h value reported in the TPM-IR
abel (Topamax®, 2009). Though the half-life value from Lambrecht
t al. may  seem contradictory to the Topamax prescribing infor-
ation, this discrepancy in t1/2z is likely due to methodology and
ot due to an actual difference in half-life. For example, the sensi-
ivity of the PK assay was increased for Lambrecht and colleaguesparative pharmacokinetic analysis of USL255, a new once-daily extended-release
diate-release topiramate; USL255, extended-release topiramate.
versus the Topamax prescribing information (10 ng/mL lower limit
of quantiﬁcation [LLOQ] vs 500 ng/mL LLOQ, respectively); fur-
ther, Lambrecht et al. had a longer sampling duration (336 vs 32 h,
respectively). To demonstrate how sampling time can impact t1/2z,
TPM-IR and USL255 were evaluated at various time points. As sam-
pling duration increased from 48 to 336 h, the t1/2z also increased
from approximately 30 to 80 h (Fig. 2). It is important to note that
this large impact of sampling time on t1/2z is not a universal fea-
ture for all drugs; for TPM, its multi-compartment PK may make it
more sensitive to sampling time compared with a drug that does
not distribute into multiple tissue compartments (see Fig. 1A for a
hypothetical example on how sampling time may impact t1/2z).
Taken together, these data suggest that t1/2z may not accurately
represent a clinically meaningful elimination or accumulation esti-
mate of an extended-release drug, and use of t1/2z may result in an
inaccurate prediction of the appropriate dosing interval.
A limitation of these analyses is the evaluation of PK in healthy
individuals and not patients with epilepsy; as such, speciﬁc factors
that may  inﬂuence PK may  not be represented (eg, concomitant
use of cytochrome inducers or inhibitors). FDA guidance often rec-
ommends PK analyses in healthy individuals, which may limit
confounding factors, and data from healthy individuals are often
B.E. Gidal et al. / Epilepsy Research 129 (2017) 26–32 31
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imulated steady state based on mean predicted plasma concentration-time proﬁle
bbreviations: BID, twice daily; QD, once daily; TPM-IR, immediate-release topiram
sed in modeling analyses to evaluate drug PK. Further, results
rom these analyses were not intended to serve as direct clinical
utcome data. A detailed comparison of t1/2z and t1/2eff—using TPM
s a real-life example—was used to illustrate how formulation and
ethodological differences may  impact half-life values, which has
mplications in patient care.
For example, in cases where clinicians choose to implement
 dosing schedule that differs from the approved dosing recom-
endations of a given drug, understanding half-life is particularly
mportant. For patients who are already on concomitant BID drugs,
ome clinicians may  recommend taking the same total daily dose
f a QD drug (with a long half-life) twice daily to potentially reduce
lasma ﬂuctuations and simplify the overall drug regimen. Con-
ersely, a clinician may  assume that a BID drug with an ∼24-h
alf-life could be administered QD. For example, the 21-h reported
1/2z for TPM-IR (Topamax®, 2009) may  be interpreted to mean QD
osing is acceptable. However, QD dosing may  not be optimal based
n the predicted steady-state proﬁle of TPM-IR, which showed
ncreased plasma ﬂuctuations compared with TPM-IR BID (Fig. 3).
hese data, using TPM as an example, underscore the importance
f understanding the clinical relevance of half-lives reported in a
rug’s prescribing information. Additionally, while half-life may  be
ne parameter used to guide dosing, assessing the entire steady-
tate proﬁle may  provide additional information when optimizing
 dosing regimen.
It is important to note that neither t1/2z nor t1/2eff for USL255 and
PM-IR are identical to recommended dosing intervals for these
rugs. This is because half-life alone may  not provide all of the
nformation necessary to construct an appropriate dosing regimen,
s additional pharmacodynamic effects of a drug (eg, therapeu-
ic index and receptor binding afﬁnity/duration of binding) may
nﬂuence drug distribution. Additionally, drugs can be dosed more
requently than recommended by half-life values, as dosing may  be
ptimized to decrease ﬂuctuations in plasma concentrations.
USL255 was developed to provide relatively consistent plasmarug concentrations across a 24-h dosing interval with reduced
uctuations compared with TPM-IR (Bialer et al., 2013). This is sup-
orted by the steady-state simulations shown here, which revealedM-IR Administered QD or BID.
00 mg/day USL255 and TPM-IR once- or twice-daily are shown.
SL255, extended-release topiramate.
that USL255 QD had a smaller ﬂuctuation index and higher Cmin
than TPM-IR QD or BID (Fig. 3). The mean predicted ﬂuctuation
index for USL255 QD was reduced by 18% compared with TPM-
IR BID, which is slightly lower than the observed 26% decrease
in ﬂuctuation index with USL255 QD versus TPM-IR BID follow-
ing steady-state dosing in healthy volunteers (Bialer et al., 2013).
This difference may  be due in part to limitations in our methodol-
ogy; while data from the Bialer et al. study were used to estimate
t1/2eff for USL255 and TPM-IR, the models used here were from the
literature. Therefore, the proﬁles in this analysis were developed
using 2 different data sets (ie, not the same participants).
The predicted steady-state proﬁles for USL255 and TPM-IR pro-
vide a better understanding of XR versus IR topiramate PK, which
may  be considered when determining drug choice and dosing. In
general, XR AEDs tend to have reduced plasma ﬂuctuations and
ﬂatter plasma concentration-time curves than their IR counter-
parts (Pellock et al., 2004), a pattern that also was observed for
USL255 and TPM-IR. A ﬂatter steady-state curve for XR AEDs may  be
favorable for patients who require dosing adjustments, particularly
increased doses, to maintain seizure control without precipitating
any adverse events associated with peak concentrations (Pellock
et al., 2004).
5. Conclusions
The commonly referenced elimination half-life (t1/2z) may  not
be adequate or appropriate in many circumstances. Effective half-
life, or t1/2eff, may  indeed be more clinically relevant as it takes into
consideration the entire concentration-time proﬁle of a drug. This
is particularly true when comparing dosing requirements between
immediate and extended-release product formulations. However,
half-life is not the only parameter used to determine dosing regi-
mens. The importance of recommended dosing from prescribing
information is illustrated by the simulations of TPM-IR; while
once-daily dosing may  seem appropriate with its long reported
half-life, doing so may  result in large plasma ﬂuctuations. Together
with the comparison of t1/2eff and t1/2z, these data underscore the
3 y Rese
i
c
D
b
U
e
m
t
o
i
A
b
b
b
G
I
R
B
B
dosage forms. Pharm. Res. 25, 2869–2877.2 B.E. Gidal et al. / Epileps
mportance of understanding half-life measures, and may  improve
linicians’ understanding of dosing regimens.
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